Real-World Evidence of Treatment Patterns and Costs of Turner Syndrome and Noonan Syndrome in the USA
Authors' conclusion
Of the few patients on GH therapy, less than half were initiated on treatment early after their TS or NS diagnosis. Greater awareness regarding early diagnosis and treatment of TS and NS is needed.
Study context
- Population
- Patients with Turner syndrome (TS) (aged 4 to <14 years) or Noonan syndrome (NS) (aged ≤18 years) in a US claims database, 2016–2022, with ≥6 months baseline and ≥1 year follow-up
- Participants
- 2,530 vs 1,119
- Exposure
- TS vs NS
- TSn = 2,530
- NSn = 1,119
- Outcome
- Initiated growth hormone (GH) treatment during follow-up
Methodological detailsclaims database (Komodo Health), descriptive analysis
- Claims database (Komodo Health)
- Descriptive analysis
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Early initiators (started ≤6 months post-index), among GH-treated
High adherence (≥80% of GH treatment days covered), among GH-treated
Long persistence (treated ≥2 years), among GH-treated
GH treatment duration
Median USD
| Outcome | TS | NS |
|---|---|---|
| Total all-cause costs per patient/year | 10,232 (IQR USD 2,850-USD 36,590) | 17,937 (IQR USD 5,616-USD 47,552) |
Original publication
Real-World Evidence of Treatment Patterns and Costs of Turner Syndrome and Noonan Syndrome in the USA. Horm Res Paediatr. Published 20 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →